Equities research analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
TTNP stock opened at $3.20 on Friday. The firm has a 50-day moving average price of $3.67 and a 200-day moving average price of $4.82. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Insider Trading – What You Need to Know
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- The 3 Best Blue-Chip Stocks to Buy Now
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.